Search Insights

Insights

39 Insights found for Nelson, Kevin M
TITLE
Event

Take Your Legal Writing from Good to Great - Drafting Tips from the Pros

American Bar Association, Landslide Webinar Series

Event

COVID-19 Legal Issue Spotting for In-House Counsel

Schiff Hardin LLP

Location:
Webinar
Event

Inherent Obviousness: A Case Study on a Less Known but Effective Defense

9th Annual Pharma IPR Conference 2020

Location:
Mumbai, India
Event
News Release

99 Schiff Hardin Attorneys Named to 2017 Leading Lawyers List

Ninety-nine Schiff Hardin lawyers have been named to the 2017 Leading Lawyers list for Illinois and Michigan.

In The News
News Release

Schiff Hardin Expands Global Generic Pharmaceuticals Practice With Addition of Kevin M. Nelson in Chicago

Schiff Hardin LLP today announced the addition of Kevin M. Nelson as a partner in its rapidly growing Intellectual Property Group.

News Release

95 Schiff Hardin Lawyers Named to 2018 Leading Lawyers Lists

Ninety-six Schiff Hardin lawyers have been named to the 2018 Leading Lawyers lists for Illinois and Michigan.

News Release

Schiff Hardin Secures Patent Infringement Win

Schiff Hardin successfully secured a favorable outcome for our client, Fresenius Kabi USA LLC, in a patent-infringement suit filed by Hospira Inc., which paves the way for Fresenius to market a new generic drug.

News Release

2019 Leading Lawyers Lists Recognize 95 Schiff Attorneys

Schiff Hardin LLP is pleased to have 95 attorneys named to the 2019 Leading Lawyers list.

In The News
News Release

Schiff Hardin Advises Snap-on in Power Hawk Acquisition

Schiff Hardin LLP represented Snap-on Incorporated (NYSE:SNA), a manufacturer and marketer of tools, equipment, diagnostics, repair information and systems solutions, in its acquisition of Power Hawk Technologies for approximately $8 million.

News Release

Eighty-Eight Attorneys Named to 2020 Leading Lawyers

Schiff Hardin LLP is pleased to announce that 88 attorneys have been named to the 2020 Leading Lawyers list.

News Release

Firm and Four Attorneys ranked in the 2020 IAM Patent 1000

Schiff Hardin LLP is proud to announce that the firm and four of its attorneys have been ranked in the ninth edition of IAM Patent 1000: The World’s Leading Patent Professionals, a guide that identifies top patent professionals based on 1,800 interviews with private practice and in-house professionals.

News Release

Schiff Hardin Wins Patent Infringement Appeal

Schiff Hardin won an appeal for our client, Fresenius Kabi USA LLC, in a patent-infringement suit filed by Hospira Inc., showing a formulation patent claim is invalid and helping generics further develop the “inherent obviousness” case law.

News Release

Thirty-Two Attorneys Named to 2020 Super Lawyers and Rising Stars Lists

We are pleased to announce that 32 Schiff Hardin attorneys have been recognized on the 2020 Illinois Super Lawyers and Rising Stars lists.

Article
Article

What if Pfizer Could Donate Data to NIH? One Proposal to Promote Public Good

Pfizer’s recent decision not to disclose data about Enbrel’s potential to treat Alzheimer’s disease has caused much debate about drugmakers’ obligations to the public.

Alert

Clinical Trial Impact from Coronavirus: New FDA Guidelines for Safety and Integrity

The U.S. Food and Drug Administration (FDA) issued a guidance document today outlining its procedures for conducting clinical trials of investigational products in view of the worldwide COVID-19 outbreak.

Alert

Congress CREATES a New Action to Combat Drug Approval Delays

Lost in the proceedings that have occupied our collective attention these last few months was the passage of the omnibus “Further Consolidated Appropriations Act, 2020,” which became law in late December and kept our country operating (at least for the near term).

Alert

If Successful, Teva Suit Could Decrease Generic Competition

Teva Pharmaceuticals filed suit against the United States Food and Drug Administration (FDA) alleging that its glatiramer (Copaxone) falls under the revised definition of a “biological product” and should be transitioned to the system established by the Biologics Price Competition and Innovation Act of 2009 (BPCIA).

Article